CUSIP: 86627R102
Q3 2015 13F Holders as of 30 Sep 2015
-
Type / Class
-
Equity / Stock
-
Total 13F shares
-
2,838,493
-
Share change
-
+52,380
-
Total reported value
-
$29,548,000
-
Price per share
-
$10.41
-
Number of holders
-
10
-
Value change
-
+$538,260
-
Number of buys
-
5
-
Number of sells
-
3
Quarterly Holders Quick Answers
What is CUSIP 86627R102?
CUSIP 86627R102 identifies SMMT - SUMMIT THERAPEUTICS INC COM - Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2015
-
Previous quarter:
Q2 2015
Recent filing periods for CUSIP 86627R102:
Institutional Holders of SUMMIT THERAPEUTICS INC COM - Stock (SMMT) as of Q3 2015
As of 30 Sep 2015,
SUMMIT THERAPEUTICS INC COM - Stock (SMMT) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,838,493 shares.
The largest 10 holders included
LANSDOWNE PARTNERS (UK) LLP, Point72 Asset Management, L.P., AXA, SPHERA FUNDS MANAGEMENT LTD., First Eagle Investment Management, LLC, Granite Point Capital Management, L.P., EverPoint Asset Management, LLC, WELLS FARGO & COMPANY/MN, Tower Research Capital LLC (TRC), and UBS Group AG.
This page lists
10
institutional shareholders reporting positions in this security
for the Q3 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.